ABVX:EPA
Abivax SA
77,65 €
0,00%
(0,00) 1 d.
5. nov., 17:35:35 GMT+1 · EUR
search
Visi simboli
| Simbols | Cena | Izmaiņas | % izmaiņu |
|---|
insights_autoNotiek galveno ieskatu ģenerēšana par šādu tēmu: ABVX…
Tirgus kapitalizācija
6,70 mljrd.
Vid. apjoms
111,44 tūkst.
Apjoms
0,00
Augstākā 52 ned.
139,00 €
Zemākā 52 ned.
60,45 €
Peļņa uz vienu akciju
-5,20 €
Apgrozībā esošās akcijas
87,55 milj.
Darbinieku skaits
98
Tirgus kapitalizācija
6,70 mljrd.
Vid. apjoms
111,44 tūkst.
Apjoms
0,00
Augstākā 52 ned.
139,00 €
Zemākā 52 ned.
60,45 €
Peļņa uz vienu akciju
-5,20 €
Apgrozībā esošās akcijas
87,55 milj.
Darbinieku skaits
98
Ziņas un raksti
No tīmekļa avotiem un ziņu partneriem
Investing.com
·
pirms 51 minūtes
Nasdaq Volatility Shock Warns Against Buying Too Early
Yahoo Finance
·
pirms 1 stundas
Nasdaq Stock Market Correction: 3 Words From Warren Buffett To Remember RIght Now
Yahoo Finance
·
pirms 1 stundas
Stock Market: Will S&P 500 Open Up or Down Today?
The Motley Fool
·
pirms 4 stundām
The Nasdaq Plunges 5%. What the Data Center Crash Means for Investors
Profils
Abivax SA is a clinical stage biotechnology company focused on developing innovative treatments that harness the body’s natural regulatory mechanisms to modulate the immune response in patients with chronic inflammatory diseases.
Abivax has a program in clinical development with its lead drug candidate, obefazimod, to treat ulcerative colitis. Another program in Crohn’s disease is also in preparation and other potential inflammatory indications are being evaluated.
The company’s headquarters are based in Paris, France with a US office in Waltham, Massachusetts. Abivax’s Research and development work is conducted at its research center based in Montpellier, France. Wikipedia
Par “Abivax SA”
ĢenerāldirektorsMarc de Garidel | Hartmut J. Ehrlich
Darbinieki98
Dibināšanas datums2013. gada 4. dec.
Galvenais birojs-
SektorsHealth Care
Industry-
Tīmekļa vietneabivax.com